Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors

Indian Journal of Experimental Biology

Volumn 43, Issue 7, 2005, Pages 614-619

  Shafiq, N ^a   Malhotra, S ^a   Pandhi, P ^a   Nada, R ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Celecoxib; COX 2; Gastric ulcer; Indomethacin; Ischemia reperfusion; Nimesulide; NSAIDs

Indexed keywords

CELECOXIB; INDOMETACIN; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL; ARTICLE; COLITIS; COMPARATIVE STUDY; DRUG EFFECT; GASTROINTESTINAL TRACT; INJURY; MALE; PATHOLOGY; RAT; REPERFUSION INJURY; STOMACH MUCOSA; VASCULARIZATION; WISTAR RAT;

ANIMALS; COLITIS; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; GASTROINTESTINAL TRACT; INDOMETHACIN; MALE; PYRAZOLES; RATS; RATS, WISTAR; REPERFUSION INJURY; SULFONAMIDES;

EID: 22044432297     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. MS (Intercontinental - Medical statistics) publications Pharmaceutical Database Division. (1990) IMS Ltd, Plymouth Meeting, Pennsylvania, and IMS Medical world review. UK and IMS, 1989.
2. Hawkey CJ, Nonsteroid anti-inflammatory drugs and peptic ulcers, BMJ, 300 (1990) 278.
3. Langman MJ, Weil J, Weinwright P, Lawson DH, Rawlins MD, Logan RF, Colin Jones DG, Murphy M & Vessey MP. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs, Lancet, 343 (1994) 1075.
4. Henry D, Lin LL, Garcia Rodriguez LA, Perez Guthan S, Carson JL, Griffein M, Savage R, Logan R, Moride T, Hawkey C, Hills & Fries JT. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of collaborative metaanalysis, BMJ, 312 (1996) 1563.
5. Roberts II LJ & Morrow JD, Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout, in The pharmacologal basis of therapeutics, edited by JG Hardman, LE Limbird, AG Gilman (Mc Graw Hills, New York) 2001, 687.
6. Vane JR, Bakle YS & Botting RM, Cyclooxygenase 1 and 2, Annu Rev Pharmacol Toxicol, 38 (1998) 97.
7. Rimarachin JA, Jawbson JA, Szabo P, Maclouf S, Creminon C & Weksler BB, Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells, Arterioscle Thromb, 14 (1994) 1021.
8. Sawaoka H, Tsuji S, Tsujii M, Gunaman FS, Nakama A, Takei Y, Nagano K, Matsui H, Kawano S & Heri M, Expression of cyclooxygenase -2 gene in gastric epithelium, J Clin Gastroenterol, 25 (Suppl 1) (1997) S105.
9. Gretzer B, Ehrlich K & Maricie N, Selective cyclooxygenase -2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach, Br J Pharmacol, 123 (1998) 927.
10. Nakatsugi S, Terada N, Yoshimura T, Horie Y & Furukawa M. Effects of nimesulide, a preferential cyclooxygenase - 2 inhibitor on carraagenan induced pleurisy and stress induced gastric lesions in rats, Prostaglandins leukotrienes Essent Fatty Acids, 55 (1996) 395.
11. Wallace JL, Render BK, McKnight W, & Bak A, Selective inhibition of cyclooxygenase - 2. Are they really effective, selective and GI safe, J Clin Gastroenterol, 27 (Suppl 1) (1998) S28.
12. Ladanno OM, Cesori JA, EC Narriager J, Esharriaga J, Rista L & Piombo G, Gastrointestinal damage induced by celecoxib and rofecoxib in rats, Acta Gastroenterol Latinoam, 30 (2000) 27.
13. Maricis N, Ehrlich K, Gretzer B, Sehtiligoi R, Respondek M & Peskar BM, Selective cyclooxygenase - 2 inhibitors aggravate ischemia - reperfusion injury in the rat stomach, Br J Pharmacol, 128 (1999) 1659.
14. Reuter BC, Asfaha S, Buret A, Shaxkey KA & Wallace JL, Exacerbation of inflammation associated colonic injury in rat through inhibition cyclooxygenase-2, J Clin Invest, 98 (1996) 2076.
15. Wallace J, Selective COX-2 inhibitors: is the water becoming muddy, Trend Pharmacol Sci, 20 (1999) 4.
16. Merris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR & Wallace JL, Hapten-induced model of chronic inflammation and ulceration in the rat colon, Gastroenterology, 96 (1989) 795.
17. Seibert K, Zhang Y, Leahyh K, Hauser S, Masferrer J & Perkins W, Pharmacological and biochemical demonstration of the role of cyclooxygenase - 2 in inflammation and pain, Proc Natl Acad Sci, USA 91 (1994) 12013.
18. Chan CC, Boyce S, Brideau C, Food-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M, Prasit P, Rasori R, Riendean D, Roy P, Tagari Pl Vickers P, Wong E & Rodger IW, Pharmacology of selective cyclooxygenase-2 inhibitor, L-745, 337: a novel nonsteroidal agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach, J Pharmacol Exp Ther, 274 (1995) 1531.
19. Futaki N, Yoshikawa K, Hamsaka Y, Avai JI, Higuchi S, Hsuka H & Ofomos, NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects which causes minimal stomach lesions, Gen Pharmacol, 24 (1993) 105.
20. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC & Geis GS, Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase - 2 inhibitor: efficacy and safety in two placebo controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum, 41 (1998) 1591.
21. Emery P, Zeidler H, Kvein TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC & Geis GS, Celecoxib versus dichlofenac in long term management of rheumatoid arthritis: double blind comparison, Lancet, 354 (1999) 2106.
22. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA & McNaughton WK, Cyclooxygenase contributes to inflammatory response in rats and mice: implications for gastrointestinal toxicity, Gastroenterology, 115 (1998) 101.
23. Jackson LM, Wu KC, Mahinda YR, Jenkins D & Hawkey CJ, Cyclooxygenase (COX) 1 and 2 in normal, inflamed and ulcerated human gastric mucosal, Gut ,47 (2000) 762.
24. Ukawa H, Yamakuni H, Kato S & Takuchi K, Effects of cyclooxygenase -2 selective and nitric oxide releasing nonsteroidal anti-inflammatory drugs on mucosal ulcerogenic and healing responses of the stomach, Dig Dis Sci, 43 (1998) 2003.
25. Sawoka H, Kawano S, Tsuji S, Sun W, Gunawan ES & Hori M, Helicobacter pylori infection induces cyclooxygenase -2 expression in human gastric mucosal prostaglandins, Leukot Essent Fatty Acids, 59 (1998) 313.
26. Mizuno H, Sakamoto C & Matsuda K, Induction of COX-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice, Gastroenterology, 112 (1997) 387.
27. Reuter BK, Asfaha S, Buret A, Sharkey KA & Wallace JL, Exacerbation of inflammation associated colonic injury in rat through inhibition of COX-2, J Clin Invest, 98 (1996) 2076.
28. Morteau O, Morham S, Sallon R, Boroviov J, Smithies O & Sartor RB, Genetic deficiency in cyclooxygenase - 2 but not in cyclooxygenase - 1 exacerbated DSS induced acute colitis, Gastroenterology, 112 (1997) 1046.
29. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, Sautebin L & Caputi A P, A selective cyclooxygenase - 2 inhibitor reduces the severity of experimental colitis induced by dinitorobenzene sulfonic acid in rats, Eur J Pharmacol, 431 (2001) 91.
30. Kankari B, Vaali K, Korpela R, Poakkari I, Vapaatato H & Moilaner E, Effects of COX-2 preferential agent nimesulide on TNBS induced acute inflammation in the gut, Inflammation, 25 (2001) 30.
31. Tanaka A, Hase S, Miyazawa T, Takuchi K, Upregulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to non-steroidal anti-inflammatory drug induced induced intestinal damage, J Pharmacol Exp Ther, 300 (2002) 754.
32. Langenbach R, Morham SA, Tiano HF, Loftin, Ghanayem BI, Chulada PC, Mahler JF, Lee Goulding EH, Kluckman KD, Kin HS & Smithus, Prostaglandin synthase - 1 gene disruption in mice reduces arachidonic acid induced inflammation and indomethacin induced gastric ulceration, Cell, 83 (1995) 483.
33. Freitas J, Farricha V, Nascimento J, Borratho P & Parames A, Rofecoxib: a possible cause of acute colitis, J Clin Gastroenterol, 34 (2002) 451.
34. Foral PA, Wilson AF & Nystrom KK, Gastrointestinal bleeds associated with rofecoxib, Pharmacotherapy, 22 (2002) 384.
35. Bombardaidier C, Laine L, Reicin A, Shapiro D, Burgas-Varga SR, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK & Schitzer TJ, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients of rheumatoid arthritis. VIGOR Study Group, N Engl J Med, 343 (2000) 1520.
36. Hrach Hovec JB, Reporting of 6 - month vs 12 month data in a clinical trial of Celecoxib, JAMA, 286 (2001) 2398.